Oligometastatic disease has been proposed as an intermediate state between localised and
systemically metastasised disease. In the absence of randomised phase 3 trials, early …

Abstract Introduction/Background An individual patient data metaanalysis was performed to
determine clinical outcomes, and to propose a risk stratification system, related to the …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Importance Complete metastatic ablation of oligometastatic prostate cancer may provide an
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …

Background Recognizing the rapidly increasing interest and evidence in using metastasis-
directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO …

Background Evidence from retrospective studies suggests that disease progression after first-
line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …

Metastasis is associated with poor prognosis in breast cancer patients. Not all cancer cells
within a tumor are capable of metastasizing. The microRNA-200 (miR-200) family, which …

The oligometastasis hypothesis suggests a spectrum of metastatic virulence where some
metastases are limited in extent and curable with focal therapies. A subset of patients with …

The oligometastatic state has been proposed as an intermediate stage of cancer spread
between localized disease and widespread metastases. With improvements in diagnostic …

Background Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment
option for patients with oligometastatic disease. SABR delivers precise, high-dose …